Posted 5th November 2018 by Kate Barlow
The histological assessment of human tissue has emerged as a key challenge for the detection and treatment of cancer. Many tissue sections have to be processed in order to find those that contain cancer, which can be a timely and costly process. Similarly, procedures such as immunohistochemical scoring can be problematic for cases such as ER, PR, and HER2.
Posted 8th October 2018 by Kate Barlow
Over recent years, we have seen record numbers of skin cancer diagnoses around the world. Indeed, since the 1980s, incidences of melanoma, the deadliest form of cancer, have doubled. Melanoma is an aggressive form of cancer that can spread to other organs and is estimated it will kill 10,000 people in the US this year. Approximately 3 million Americans will be diagnosed with skin cancer this year in the US.
Posted 5th October 2018 by Kate Barlow
There are currently more than 120 biobanks worldwide. While most focus on genomic research and personalised medicine, biobanks range in size. Small operations have just a few freezers which are kept in a researcher’s laboratory, a clinical laboratory, or a pathology suite, while the larger, commercial ones support large clinical and epidemiological suites. In addition, the storage of samples tends to vary:
Posted 24th September 2018 by Kate Barlow
Thanks to advancements in human tissue sample procedures, we have been able to make major breakthroughs in cancer research. In the twenty-first century, epidemiological and clinical evidence have supported the claim that changes in metabolism can affect oncogenesis and tumour response to therapy.
It has been observed that metabolic conditions such as hyperglycemia, obesity, hyperlipidemia, and insulin resistance are directly associated with increased risk of cancer development as well as the acceleration of tumour progression. These findings indicate that statins and metformin may help decrease cancer-related deaths.
Posted 30th July 2018 by Kieran Chambers
There has been some interesting news, discoveries and development to catch up on this month in the world of precision medicine. Take a look at the list below to find out more:
Posted 14th May 2018 by Anna Gomez
Our understanding of the aberrant biological pathways (oncogenic pathways) that are involved in the formation and progression of cancers has increased with huge leaps in the last decades of cancer research. The ever-increasing knowledge was and still is accompanied by the development of increasing numbers of precision drugs, tailored to neutralize these aberrations.
Posted 30th April 2018 by Anna Gomez
Industrial and “omic” scale mutational profiling of solid tumours are possible as a result of massively parallel sequencing technology. However, these clinical genomic testing capabilities have also brought myriad new biological, technical and operational challenges not encountered in monogenic disorder testing. All of this impacts the interpretation and reporting of somatic variants. As a testament to the nascency of this field, the first published consensus guidelines for interpretation of variants in cancer was only released in early 2017.